CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shanghai Rightongene Biotechnlgy Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shanghai Rightongene Biotechnlgy Co Ltd
#6055 Jinhai Expressway
Fengxian District, Building 3
Phone: +86 2133282601p:+86 2133282601 Shanghai, SHA  201403  China Ticker: 688217688217
Business Summary
Shanghai Rightongene Biotechnology Co Ltd is a China-based company principally engaged in the research and development, production and sales of in-vitro diagnostic products, as well as the provision of scientific research and testing services. The Company's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The Company mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The Company also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The Company mainly conducts its businesses within domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager HuiXiong 50
Chief Financial Officer, Finance Director, Secretary of the Board YanLi 40 10/1/2021 3/1/2020
Deputy General Manager, Director JunXiong 46 1/1/2015 1/1/2015
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 501 (As of 12/31/2023)
Outstanding Shares: 55,855,896 (As of 1/30/2024)
Shareholders: 5,317
Stock Exchange: SHA
Fax Number: +86 2137199015


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024